<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718051</url>
  </required_header>
  <id_info>
    <org_study_id>N202007032</org_study_id>
    <nct_id>NCT04718051</nct_id>
  </id_info>
  <brief_title>S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheng Pu Pharmaceutics Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the Westernization of the diet and insufficient exercise, Taiwan's population of&#xD;
      obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of&#xD;
      the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary&#xD;
      adjustments, and certain drug treatments can delay the deterioration of the disease; however,&#xD;
      weight loss and dietary adjustment are not easy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the Westernization of the diet and insufficient exercise, Taiwan's population of&#xD;
      obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of&#xD;
      the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary&#xD;
      adjustments, and certain drug treatments can delay the deterioration of the disease; however,&#xD;
      weight loss and dietary adjustment are not easy. Moreover, drugs also have side effects, and&#xD;
      there is currently no convenient and effective treatment for people who have non-alcoholic&#xD;
      fatty liver disease. The purpose of this trial is that investigating and evaluating the&#xD;
      effects on fatty liver, liver fiber, and metabolic indexes after subjects using Shen Pu Yang&#xD;
      Gan Wan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AST index</measure>
    <time_frame>36 weeks</time_frame>
    <description>Measure the changes in the index which is AST relate to Liver inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ACT index</measure>
    <time_frame>36 weeks</time_frame>
    <description>Measure the changes in the index which is ACT relate to Liver inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>36 weeks</time_frame>
    <description>Measure the changes in the index which is HbA1c relate to Liver inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibroscan</measure>
    <time_frame>36 weeks</time_frame>
    <description>Measure the changes in the index which is Liver Fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring Body Mass Index</measure>
    <time_frame>36 weeks</time_frame>
    <description>Measuring Body Mass Index (BMI). Measure the changes in index which is Metabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Shen Pu Yang Gan Wan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traditional Chinese Medicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shen Pu Yang Gan Wan</intervention_name>
    <description>Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.</description>
    <arm_group_label>Shen Pu Yang Gan Wan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with fatty liver diagnosed by abdominal ultrasound or hepatic fibrometer&#xD;
             within half a year's data&#xD;
&#xD;
          -  Subjects with the non-alcoholic fatty liver disease&#xD;
&#xD;
          -  The severity of fatty liver should be at least 3 points by taking an abdominal&#xD;
             ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients with viral hepatitis.&#xD;
&#xD;
          -  Long-term drinkers.&#xD;
&#xD;
          -  Those who use slimming products and vitamin E.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shun Wu</last_name>
    <role>Study Director</role>
    <affiliation>Taipei Municipal Wanfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shun Wu, PHD</last_name>
    <phone>+886229307930</phone>
    <email>vw1017@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Wenshan District</state>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shun Wu</last_name>
      <phone>0229307930</phone>
      <phone_ext>1248</phone_ext>
      <email>mswu@tmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, Wang CC, Tsukamoto H. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor Î³ in hepatic stellate cells for their antifibrotic effect. Hepatology. 2012 Apr;55(4):1271-81. doi: 10.1002/hep.24792. Epub 2012 Mar 1.</citation>
    <PMID>22095555</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

